Andere talen BioMarin Pharmaceutical Inc.

Aandelen

BMRN

US09061G1013

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 15-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
91,51 ^USD	-0,77%		+4,85%	-5,09%

15/04	Biomarin Pharmaceutical Insider verkocht aandelen ter waarde van $3.645.000, volgens een recent SEC-document	MT
01/04	Biomarin Pharmaceutical Insider verkocht aandelen ter waarde van $2.173.341, volgens een recent SEC-document	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing	15/04
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET	10/04
Biomarin Pharmaceutical Insider Sold Shares Worth $2,173,341, According to a Recent SEC Filing	01/04
New Data to be presented for BioMarin's VOXZOGO in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting	13/03
BioMarin Pharmaceutical Says Voxzogo Leads to Height Gains in Children With Achondroplasia	12/03
ETF der Woche: Auf die Wende der Biotechs setzen	10/03
L'ETF della settimana: scommettere sull'inversione di tendenza delle biotech	09/03
ETF de la semaine : miser sur le retournement des Biotechs	08/03
Biomarin Pharmaceutical Insider Sold Shares Worth $348,280, According to a Recent SEC Filing	07/03
BioMarin Pharmaceutical Appoints Cristin Hubbard as Chief Commercial Officer	07/03
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer	07/03
Biomarin Announces Board Changes, Effective May 20, 2024	07/03
BioMarin Scheduled to Participate in March Investor Conferences	04/03
BioMarin Scheduled to Participate in March Investor Conferences	01/03
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme -- Update	26/02
BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies	26/02
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme	26/02
BioMarin Pharma gets DOJ subpoena on certain drug testing programs	26/02
BioMarin: Q4 Earnings Snapshot	22/02
BioMarin Pharmaceutical Q4 Adjusted Earnings, Revenue Rise, 2024 Outlook Set -- Shares Decline After Hours	22/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BioMarin Pharmaceutical Inc.

Aandelen

BMRN

US09061G1013

Andere talen

Filters